Exploring Barriers and Facilitators to Patients and Members of the Public Contributing to Rapid Health Technology Assessments for NICE: A Qualitative Study.

Background: Evidence and External Assessment Groups (EAGs) assist in the National Institute of Health and Care Excellence's Technology Appraisal programme by either critiquing evidence provided by companies on different health technologies, or by carrying out an independent search and evaluation of the published evidence. Historically, there has been little patient and public involvement within the work of EAGs.

Objective: To identify key barriers and facilitators to patient and public involvement in EAG Reports feeding into the National Institute for Health and Care Excellence's Health Technology Appraisal process.

Reporting of Patient and Public Involvement in Technology Appraisal and Assessment Reports: A Rapid Scoping Review.

Background: The National Institute for Health and Care Excellence (NICE) produces guidance on the use of health technologies (including new and existing medicines, medical devices, diagnostics and interventional procedures) in the National Health Service. Technology Appraisals inform recommendations on the use of new and existing health technologies. As part of its health technology evaluation process, NICE ask independent research groups known as Evidence or External Assessment Groups (EAGs) to assess or evaluate the available evidence surrounding health technologies.

Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis.

Background: Neonates with suspected sepsis are commonly treated with gentamicin, an aminoglycoside. These antibiotics are associated with high risk of ototoxicity, including profound bilateral deafness, in people with the m.1555A>G mitochondrial genetic variant.

Emerging Technologies for Improving Musculoskeletal Health: A Systematic Evidence Gap Map.

Introduction: Musculoskeletal (MSK) conditions are the largest contributor to disability worldwide. The aim of this project was to undertake a horizon scan and generate an evidence gap map (EGM) to highlight technological innovations in development for preventing and managing MSK conditions at early stages of the clinical treatment pathway, and to identify areas of unmet need.

Methods: In February 2024, bibliographic databases, a clinical trial registry, research funding portals, and company websites were searched for relevant records.

Cariprazine in the acute treatment of unipolar and bipolar depression: A systematic review and meta-analysis.

Background: Cariprazine has emerged as a promising augmenting treatment agent for unipolar depression and as a monotherapy option for bipolar depression. We evaluated cariprazine's efficacy in treating acute major depressive episodes in individuals with major depressive disorder (MDD) or bipolar disorder.

Methods: A systematic review was conducted on MEDLINE, Embase, PsycINFO, Scopus and Web of Science, ClinicalTrials.